MTHFR Compound Heterozygous: Clinical Significance
Compound heterozygous MTHFR genotypes have minimal to no clinical significance for thrombosis, cardiovascular disease, or pregnancy complications, and routine testing is not recommended. 1
Current Guideline Position
The American College of Medical Genetics and Genomics (ACMG) explicitly does not recommend routine MTHFR variant testing for thrombophilia, recurrent pregnancy loss, or other adverse perinatal events 1. This position is supported by:
- American College of Obstetricians and Gynecologists (ACOG)
- British Committee for Standards in Haematology
- British Society for Haematology
Why MTHFR Testing Lacks Clinical Utility
The two common MTHFR polymorphisms (c.665C>T [p.Ala222Val] and c.1286A>C [p.Glu429Ala]) reduce enzyme activity and are prevalent across ethnic groups 1. While it was previously hypothesized that reduced MTHFR activity might lead to mild hyperhomocysteinemia and increase risks for venous thromboembolism (VTE), coronary heart disease, and recurrent pregnancy loss, recent meta-analyses have shown no significant association between MTHFR variants and these conditions 1.
Key Evidence Points:
- The MTHFR 677C>T variant by itself is NOT associated with arterial thrombosis in the absence of hyperhomocysteinemia 2
- The variant is NOT associated with venous thrombosis in any case 2
- Homozygosity for the 677C>T variant increases risk for hyperhomocysteinemia, which in turn increases arterial thrombosis risk, but the variant alone does not 2
When MTHFR Genotype DOES Matter
Severe MTHFR Deficiency (Rare)
Compound heterozygosity becomes clinically significant only when involving true pathogenic mutations (not common polymorphisms) causing severe MTHFR deficiency 3, 4:
- Presents with major hyperhomocysteinemia (>30-100 μmol/L)
- Homocystinuria
- Progressive neurological distress
- Can present in first weeks of life with fatal outcomes if untreated 3
- Requires treatment with betaine, B vitamins, and folate 3, 5
Distinguishing Common Polymorphisms from Pathogenic Mutations
If a patient has compound heterozygosity for:
- Common polymorphisms (C677T and A1298C): No clinical action needed
- One common polymorphism + one rare pathogenic mutation: May cause intermediate hyperhomocysteinemia (30-100 μmol/L) and require treatment 4
What to Do Instead of MTHFR Testing
Measure plasma homocysteine levels directly rather than MTHFR genotyping 2. This is more informative because:
- Homozygosity for MTHFR 677C>T accounts for only about one-third of hyperhomocysteinemia cases 2
- Multiple factors affect homocysteine levels (vitamin B6, B12, folate deficiency, renal function, medications)
- Treatment decisions should be based on actual homocysteine levels, not genotype
Treatment Thresholds:
- Moderate hyperhomocysteinemia: 15-30 μmol/L - consider treatment if symptomatic
- Intermediate hyperhomocysteinemia: 30-100 μmol/L - treat with folate ± B vitamins
- Severe hyperhomocysteinemia: >100 μmol/L - requires aggressive treatment 6
Common Pitfalls to Avoid
Do not order MTHFR testing as part of thrombophilia workup - it provides no actionable information for common polymorphisms 1
Do not attribute thrombotic events to compound heterozygous MTHFR polymorphisms - look for other causes (Factor V Leiden, Prothrombin 20210A, protein C/S deficiency, antithrombin deficiency)
Do not withhold oral contraceptives based solely on MTHFR polymorphisms - there is no established contraindication
If homocysteine is elevated, treat the hyperhomocysteinemia regardless of MTHFR genotype with folate (400 μg/day), B12, and B6 as needed 6
Bottom Line
For the vast majority of patients with compound heterozygous MTHFR genotypes involving common polymorphisms (C677T and A1298C), no clinical action is required. The genotype does not predict thrombosis risk, does not require anticoagulation, and should not influence decisions about oral contraceptives, pregnancy management, or cardiovascular risk stratification. If clinical concern exists, measure homocysteine levels directly and treat based on those results, not the genotype.